Thoracic trauma represents one of the most significant causes of mortality and morbidity in trauma patients worldwide, with substantial clinical and socioeconomic implications. Blunt thoracic trauma carries an alarming mortality rate ranging from 10% to 25% (Hoogma et al., 2024). The management of blunt thoracic trauma has been subject to ongoing clinical debate and evolution over decades. Traditionally, treatment protocols have centered around two fundamental principles: immobilization and analgesia. However, research focus has been disproportionately directed toward various immobilization techniques, including mechanical stabilization methods and ventilatory support strategies (Gamberini et al., 2025; Gola et al., 2020). This research imbalance has resulted in relatively fewer evidence-based innovations in pain management protocols despite its critical importance. Current literature increasingly recognizes that pain control and immobilization should be considered equally essential components in the comprehensive management of thoracic trauma patients.

Effective pain control represents a crucial determinant of patient outcomes following thoracic trauma. The successful management of pain has been demonstrated to significantly reduce morbidity and enhance overall patient satisfaction during the recovery process (Feray et al., 2023). Pain associated with blunt thoracic trauma, particularly in cases involving rib fractures, can severely impair respiratory mechanics, leading to reduced lung volumes, inadequate clearance of secretions, and potentially progressive atelectasis (Cha et al., 2021; Chin et al., 2021). These complications can subsequently result in pneumonia, respiratory failure, and prolonged hospitalization if pain remains inadequately controlled. Despite this clinical significance, comprehensive research specifically examining pain control strategies in thoracic trauma remains relatively limited compared to other aspects of management (Koushik et al., 2023; Lazar et al., 2024; Lodhia et al., 2023; Mohamed et al., 2024; Mukherjee et al., 2023; Niazi et al., 2025). Sodium aescinate (SA), a triterpene saponin extract from horse chestnut seeds, demonstrates multiple therapeutic properties and finds extensive application in clinical practice for treating edema and inflammatory conditions (Xi et al., 2025). Studies have investigated sodium aescinate in acute lung injury. It can mitigate oleic acid-induced acute lung injury by modulating the levels of SOD, MDA, and MMP-9 in plasma and lung tissue (Wei et al., 2011). However, research on sodium aescinate in blunt thoracic trauma remains limited.

To explore novel approaches for pain management after trauma, we retrospectively analyzed patient data comparing the effects of a combination therapy of opioids and glycyrrhetinic acid (saponin) with monotherapy using opioids alone. Our analysis focused on three primary outcomes: assessing the differences in analgesic effects between the two groups, evaluating the impact of each treatment on respiratory parameters, and determining the effectiveness of the combined therapy in mitigating adverse effects associated with opioid use alone.

Our primary finding reveals that the combination of opioids and Sodium Aescinate effectively alleviates pain in blunt thoracic trauma patients while significantly reducing required opioid dosages. This reduction directly translated to a marked decrease in opioid-related adverse effects, including nausea and constipation. The combination therapy significantly improved respiratory parameters, with Group B (combination therapy) demonstrating higher FEV1 and FVC values and lower PCO2 levels compared to Group A (opioid monotherapy). These improved respiratory mechanics subsequently contributed to shorter hospital stays and reduced hospitalization costs for patients receiving the combined regimen. These findings are particularly relevant given that blunt thoracic trauma represents the majority of thoracic trauma cases and encompasses both soft tissue and bone injuries, including rib fractures that affect approximately two-thirds of chest trauma patients. The prevalence of complications in blunt thoracic trauma patients underscores the need for optimized treatments that minimize respiratory complications while providing adequate pain control. Future studies should validate whether age-specific benefits exist.

The efficacy of the combined therapy can be explained through complementary mechanisms of action. Pain in blunt chest trauma patients arises from multiple pathways, including inflammatory responses that lead to hyperemia, increased peripheral capillary permeability, and tissue exudation (Polycarpou and Kim, 2021; Schnadthorst et al., 2023). These processes result in tissue swelling and increased tension, exacerbating pain sensation. Sodium Aescinate appears to inhibit serum lysosomal activity, stabilize lysosomal membranes, prevent protease metabolism, and reduce capillary permeability—all contributing to decreased exudation and subsequent pain (Sharma et al., 2022; Stopenski et al., 2022). Additionally, it affects vascular endothelial cell receptors, causing constriction of capacitance vessels and enhancing venous return, which reduces venous congestion and tissue swelling. By addressing these underlying inflammatory mechanisms, Sodium Aescinate provides a pathway for pain relief that is complementary to the direct analgesic effects of opioids, thereby allowing for dose reduction of the latter while maintaining effective analgesia (Szamborski et al., 2022; van Zyl et al., 2024).

The management of blunt thoracic trauma has consistently posed significant challenges to thoracic surgeons. Despite extensive research, a universally recognized optimal treatment modality remains elusive. Current management strategies have centered on immobilization, chest physiotherapy, and effective pain control. Adequate analgesia remains the cornerstone of successful management as it enhances respiratory mechanics, whereas uncontrolled pain causes splinting and guarding, leading to reduced tidal volumes, decreased mobility, and impaired ability to cough and clear secretions (Sharma et al., 2022; Simon and Wickham, 2019). Various pain control strategies have been employed clinically, including intravenous narcotics, local rib blocks, pleural infusion catheters, paravertebral blocks, and epidural analgesia (Polycarpou and Kim, 2021). Each method presents distinct advantages and limitations. Epidural analgesia has gained advocacy in numerous studies due to its minimal effects on respiratory depression, somnolence, and gastrointestinal symptoms. However, it is not universally applicable due to several drawbacks. The procedure requires specialized technical expertise and carries potential complications including hypotension, epidural infections, hematoma, and spinal cord trauma (Almeida, 2021). It is contraindicated in patients with fever, coagulation abnormalities, or altered mental status, and some patients resist invasive procedures regardless of efficacy. Oral analgesics remain widely accepted due to their non-invasive nature, effectiveness, and ease of administration. While non-steroidal anti-inflammatory drugs can contribute to pain management in blunt thoracic trauma, they often provide insufficient relief, necessitating opioid supplementation (Cha et al., 2021; Chin et al., 2021; Ja et al., 2020; Kourouche et al., 2018).

However, the dose-dependent side effects of opioids (nausea, vomiting, drowsiness, and constipation) limit their widespread use. The study shows that traumatic injury significantly predisposes patients to chronic opioid use, and those who develop long-term consumption face a higher subsequent mortality risk (von Oelreich et al., 2020). Prolonged opioid exposure initiates regulatory adaptations of opioid receptors—such as desensitization and internalization—that culminate in receptor tolerance. These adaptations recruit several intracellular pathways, most prominently the upregulation of the cyclic AMP/PKA cascade and activation of cAMP response element–binding signaling (Wang et al., 2019). In a randomized study of outpatient laparoscopic cholecystectomy and appendectomy patients, a 3-day multimodal regimen of acetaminophen, ibuprofen, and up to five 5 mg rescue oxycodone tablets provided effective analgesia—patients used an average of only 1.8 oxycodone tablets, and 50% required no opioids at all (Sim et al., 2019). A meta-analysis showed that postoperative bleeding rates were comparable between ketorolac (33/1304, 2.5%) and control groups (21/1010, 2.1%; OR = 1.1, 95% CI 0.61–2.06, P = 0.72) (Wick et al., 2017). These studies demonstrate the need to reduce opioid use in clinical settings to lower patient mortality and addiction risks, making multimodal treatment strategies essential.

Our findings suggest several important clinical implications. First, by reducing opioid requirements, the combination therapy significantly diminishes respiratory inhibition that could otherwise impede expectoration and potentially lead to atelectasis and pulmonary infection. The absence of RR changes in Group B, despite improved PO₂and FEV₁, suggests enhanced alveolar ventilation efficiency and reduced dead space ventilation rather than altered respiratory drive. This may result from reduced Splinting Respiration due to better analgesia, permitting deeper tidal volumes without increasing respiratory frequency. This respiratory advantage may partially explain the improved clinical outcomes observed in the combination therapy group, including enhanced ventilation function, prevention of pulmonary complications, shortened hospital stays, and reduced hospitalization costs. Second, the combination therapy represents a non-invasive, safe, and easily administered alternative. This characteristic makes it particularly valuable for patients with contraindications to invasive procedures or those with preferences for non-invasive treatment options.

Despite these promising results, several limitations warrant consideration. Although no renal adverse events occurred in our cohort, sodium aescinate carries theoretical nephrotoxicity risks in vulnerable populations (e.g., pre-existing renal impairment). We recommend cautious use in patients with eGFR <60 mL/min/1.73 m² and routine renal function monitoring during therapy. Our study did not stratify outcomes by age groups or injury severity, which could provide more nuanced insights into which patient populations might benefit most from this combination therapy. Additionally, long-term follow-up data would be valuable to assess any potential differences in chronic pain development or functional outcomes between treatment approaches. Future research should explore optimal dosing regimens, potential interactions with other commonly prescribed medications in trauma patients, and direct comparison with regional anesthetic techniques like paravertebral blocks or serratus plane blocks. Prospective multicenter trials with larger patient cohorts would strengthen the evidence base for this promising treatment approach.

Effective analgesia remains crucial in the treatment of blunt thoracic trauma. The combination of opioids with Sodium Aescinate represents a promising approach that reduces opioid dosage requirements while enhancing patient ventilation function, preventing pulmonary complications, shortening hospital stays, and lowering treatment costs. Compared to other analgesic approaches, this oral medication regimen offers advantages of being non-invasive, safe, effective, and easily administered. These findings suggest that the combined use of opioids and Sodium Aescinate could significantly improve recovery outcomes following blunt thoracic trauma and merits consideration as a standard treatment option in appropriate clinical scenarios.